Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial.

Cristina Chimenti Matteo Antonio Russo Andrea Frustaci

Published in: European heart journal (2022)

Virus-negative inflammatory cardiomyopathy benefits from immunosuppressive therapy even after long-term follow-up. Recurrence appears to respond to a new TIMIC protocol application.

Keyphrases

heart failure
oxidative stress
randomized controlled trial
clinical trial
study protocol
phase iii
stem cells
phase ii
atrial fibrillation
childhood cancer